Loading…
Loading…
GBIO (Generation Bio Co.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
GBIO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GBIO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GBIO and 80,000+ other tickers.
See exactly how GBIO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GBIO and 80,000+ other tickers.
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.
INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO's proprietary microsphere technology. Under the agreement, Samsung Bioepis will be given a full license right for the novel long-acting semag.
Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has earned an average rating of "Hold" from the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The
Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has been assigned an average rating of "Hold" from the six research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The
MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Generation Bio Co. (NASDAQ: GBIO) to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments under certain conditions is fair to Generation Bio shareholders. Halper Sadeh encourages Generation Bio shareholders to click here to learn more about their legal rights and options or contact Danie.